跳至主要内容
临床试验/NCT04215328
NCT04215328已完成不适用

Facilitated Release of Endogenous Enterokines: An Ambulatory Prospective Randomized Controlled Trial

University of Southern California2 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2014年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
16
试验地点
2
主要终点
Weight change between groups

研究概览

简要总结

The overall objective is to develop therapy for obesity and diabetes that is as effective as gastric bypass surgery but without the cost and safety concerns.

详细描述

Gastric bypass leads to rapid, sustained diabetes remission in the majority of patients who undergo this procedure and is also highly effective therapy for obesity. However, currently <1% of medically-eligible patients undergo this or other bariatric operations due to cost and safety concerns. The approach is based on data suggesting that the benefit of gastric bypass is largely due to anatomical rearrangement of the intestine which leads to accelerated delivery of nutrients to the jejunum. This rerouting of nutrients stimulates the release of multiple neural, hormonal and enterokine responses that are associated with appetite suppression and improved glucose control. In this pilot proposal the question under investigation is whether repeated rapid delivery of a mixed meal directly to the jejunum can promote weight loss and glucose control.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes on oral antidiabetic medication
  • BMI greater than or equal to 30kg/m2
  • A1C less than 9%

排除标准

  • Use of any of the following medications: dipeptide-peptidase IV (DPP-IV) inhibitors (e.g., sitagliptin), GLP-1 analogs (e.g., exenatide) or medication that could alter glucose tolerance (e.g. steroids)
  • Contraindication to tube (e.g. Prior upper gastrointestinal bleed, or history of easy bleeding, altered foregut anatomy due to obstruction or surgery)
  • Known cardiovascular disease other than controlled hypertension.
  • Pregnancy or unwilling to take contraception
  • Active esophagitis
  • Known hiatal hernia
  • Active gastric ulcer and/or duodenal ulcers,
  • Previous restrictive surgery of the gastrointestinal tract
  • Crohn's disease
  • Active cancer
  • History of gastrointestinal hemorrhage
  • Known upper gastrointestinal lesions with potential to bleed
  • Use of NSAIDs or anticoagulants
  • Psychiatric disorders other than mild depression
  • Likely inability to adhere to study protocol including alcohol or drug dependent patients
  • Type I diabetes,
  • Liver, kidney or multi-organ dysfunction.
  • Known eating disorders
  • Inability to attend scheduled or unanticipated study visits
  • Known prior abdominal problems or operations that could lead to adhesions or strictures and that could prevent the spontaneous passage of a 10 French jejunal tube if it were to dislodge distally.

结局指标

主要结局

Weight change between groups

时间窗: Day 0 to Day 14

Weight measured in kilograms taken before and immediately following the intervention period between the intervention and control group

次要结局

  • Caloric intake within and between groups(Day 0 to Day 14)
  • Change in systolic and diastolic blood pressure(Day 0 to Day 14)
  • Change in heart rate(Day 0 to Day 14)
  • Weight change within group(Day 0 to Day 14)
  • Change in waist and hip measurements(Day 0 to Day 14)
  • Changes in gut hormone levels(Day 0 to Day 14)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Elizabeth Beale

Assistant Professor

University of Southern California

研究点 (2)

Loading locations...

相似试验

Facilitated Release of Endogenous Enterokines | 临床试验